All right. Good morning. I'm Doug Schenkel. It's my pleasure to welcome Aaron Freidin, CFO of GRAIL. Aaron, thank you for being here.
Yeah, thanks for having us, Doug.
So, as GRAIL's test, Galleri, moves through FDA review, the key debate is really what approval could unlock from a reimbursement perspective, how important that is to driving broader adoption, and how this positions you and others more broadly in the context of multi-cancer screening. It is a massive opportunity. It could make a huge difference for the general population in the U.S., and of course, you have partnerships that support a potential rollout outside the U.S. more aggressively.
So, a really exciting area, a really exciting company, a really interesting time right now. In terms of just providing a roadmap for our discussion, I want to spend a little bit of time on Q3, but I don't want to spend too much time because I think that's kind of missing the point given how we're talking about the long-term opportunities for the company.
I then quickly want to pivot to what's going on with the FDA, where do we go from now, essentially, how do we think about regulatory, building off of that, of course, turning to reimbursement, and even in advance of broad reimbursement, how you can drive broader access. That really is a segue into how you're thinking about commercial adoption and the associated economics. So that's kind of the roadmap. We'll fold in some competitive dynamics as well. So, lots of great things to talk about, but let's start on Q3. Galleri volumes increased, I think it was 24%.
Yeah
year over year, but they were down sequentially and came in a little light against what you described as a softer market backdrop. Again, I do not think we are playing for quarterly volume at this point, but it was light. Why did you come up a little bit light of target, and maybe more importantly, what lessons should we take away from how things are evolving this year?
Yeah, it is a great question, and I agree, this is the short term.
Yep.
On the way to longer term. We are building and playing in this space now, so the long term, of course, is more successful. You are building awareness and so on. So Q3 was, yeah, you said up 24%. I think we are up 36% for the year. Q3 is generally our lowest, from seasonality, our lowest growth quarter. Earlier in the year, we had our NHS-Galleri readout, which of course, we missed the primary endpoint, which was the big headline, even though there was lots of really high-quality clinical utility data in there, stage 4 reduction.
We found more stage 1 and 2 cancers in our arm alone compared to all cancers found by screening in the NHS. Do not need to go through it all again. But at that point in time, we are very media sensitive. We have an employer channel. Employers stopped talking to us, really, and did not start talking to us again until the publications came out and FDA AdCom. Those things caused some slowness in the Q3 period. The self-pay space is very, I would say, volatile.
It is hard to figure out really how it is going to grow on a quarter-over-quarter basis. That is because it is very sensitive to media, things like digital health partners and so on, great channel to distribute through, but it is also impacted by how they distribute, how they spend their marketing dollars. They toned down the marketing dollars, we sell less tests.
But overall, we are really happy with 24% growth in a slow quarter. With the FDA AdCom positive votes and all the momentum around that, we are now playing with pricing elasticity to try to figure out where our price should really be to drive further expansion prior to reimbursement.
It's interesting. I think every quarter that goes by, at least in advance of FDA approval, in advance of reimbursement, I mean, there is really a consumer behavior dynamic to this right now.
Yeah.
Is that fair?
Yeah, definitely.
Doesn't sound like, as far as you can tell, there was competitive dynamics that came into play in the quarter.
Yeah, so competition is interesting. We see it adding confusion into the space. Other folks are out there. To be really clear, we all have LDTs right now. We're on the precipice of an FDA approval, cross my fingers. But right now, we're LDTs, but so everybody kind of thinks we're the same.
A physician doesn't spend a ton of time looking at the specificity, that sensitivity, and they're making comparisons that you probably shouldn't, caring about case control data versus interventional data. But what we do find is when our PCPs do get in the office, we win once they actually spend the time to invest
Once the reps are in there, yeah.
and understand, they win. So we don't lose accounts to competition, but there's 500,000 PCPs out there. So how many people aren't taking a Galleri test because they're being approached and taking one of these others? It's hard to say.
Right. It's so early to
Yeah, exactly. We really see it's adding confusion right now, but we really think with the FDA approval, that will drive differentiation, and we will be able to, if we are successful, create that differentiation.
Right. We saw what happened coming out of ASCO over the summer. Things got better, I think, in September after the AdCom, so we are learning some lessons there. Another thing you did recently was you introduced some new promotional pricing. What lessons can we take away from that?
Yeah, I mean, there is definitely elasticity in the price, which isn't surprising. It's what we have expected. We have been saying for years now that we expect the price of this test to come down over time, not go up. It's meant to be a population scale test. At any price times any population, you are going to get to a large population level, you are going to get to a large number. So, we are built for the price to come down from a lab perspective, a COGS perspective, and so on. We see this as all playing the way we are, and we are learning about how to evolve our pricing going forward.
Okay. Helpful. You still expect that to land probably in the low $500s?
I mean, the CMS from the Nancy Sewell Act
Yeah
it is reimbursed at $508 when CMS, if they make a positive NCD decision.
Okay.
We expect it to be somewhere between $500 and $600.
Okay. All right, let us pivot to FDA. Following the September FDA AdCom, which was positive, what do you view as the most important remaining considerations for investors as Galleri moves through the regulatory process?
Yeah. In my view, the AdCom did a couple really positive things. It talked about a common cancer signal. For a while, we've been saying this, our studies have shown that there's a common cancer signal, but now there's the FDA, the FDA Advisory Committee said, "There's a common cancer signal here," which means we'll be returning results for cancers.
A broad label, in our view, is where we'll land based off of all the data we've submitted. I also think it's going to, from the sector, the category, that's going to be, I think, be the bar. I think it's going to be real hard to prove that you don't have a common cancer signal, so you're going to have to compare yourself from your metrics perspective to all cancers in your studies, not just cherry-picking cancers that you do better in.
It's a different task if that's the approach you're taking.
Exactly. The FDA AdCom also talked a lot about, we found cancers that were treated with curative intent. I think 83% of the cancers that we found in PATHFINDER 2 were treated with curative intent, which is almost like a clinical utility metric. So very, very positive things there. They debated the early-
Yeah
I'm not going to avoid that.
The E.
The E, exactly. Our studies show that more than half the cancers we found are early. Their view is, but yeah, but the sensitivity to early is low. We're having that debate. I think clinically, I don't think it's going to matter. We have all the publications, we have all the studies to show we find whether there's an early claim or not. I don't think it'll be used clinically any differently. It'll be, interesting part will be, given that the FDA has what they regulate and what they don't regulate as LDTs, it'd be hard to have one company with E and other companies without. I think that'd be a challenge from their perspective.
Yep.
I'm thinking what people should look forward to is a broad label that will hopefully better support CMS reimbursement and their NCD decision.
Can you share anything on how the discussions with the FDA are going on E specifically? Are you feeling, again, that's one of the key areas of debate based on how those discussions are progressing. It sounds like you feel okay about the E question.
Yeah, it's a key area of debate for sure. I feel good about where we're at.
Okay. The way we've positioned it, the way we're thinking about it based on our look at the data, our understanding of the biology, and importantly, what we've heard from folks who know the science really well, is in a world where the FDA is requiring very high, 99% plus specificity in an assay for that assay to be considered safe.
Inherently, the trade-off is going to be low sensitivity, especially in early-stage cancers. In many cancers, to be balanced about this, your stage 1 sensitivity is a lot lower than you would see in assays where the specificity is around 90%.
Right.
But that's the biology.
And I think what we've seen from others, and we've seen across your studies, is when you do robust, large, well-designed studies, especially ones that are actually prospective and randomized and not case-controlled, the biology is what it is.
So, one, I want to make sure you agree with my characterization, and then two, if that characterization is right, if the FDA were not to approve this, wouldn't this be a major category issue for multi-cancer detection tools by definition?
Yeah, so I agree that it's a biology safety trade-off-
Yep
at the end of the day.
Yep.
If you are okay sending 100 people to get a colonoscopy, but only five of them actually have colon cancer, that's your 90% specificity for tests that exist today. But you'd be doing that for all cancers. You can do a trade-off like that when it's a single organ. We've kind of accepted that deal. I think it'd be hard to do that with a multi-cancer test.
Then, yeah, the biology, just where's your cut point? You're going to have some things fall below your threshold. I think if the FDA says there's no early claim or early word anywhere, then yeah, I don't think it changes what a clinician does. I think it changes the way people talk about MCDs or MCEDs.
Yep. Yeah, it seems one way or the other highly likely that you would get an approval at some point in the first quarter, maybe early first quarter.
If that's the case, then there's this question about the E, and we've talked about that a little bit. From a commercial standpoint, let's say that the label were more narrow and it didn't have the letter E in it. It didn't have early in it. The assay is still the assay, and you're still on track to progress to the next discussion with CMS. Is that right?
Yeah, exactly.
Okay.
It doesn't change the reimbursement. It doesn't change the CMS discussion. In fact, it doesn't, other than taking, my understanding is, other than having the word early in it, the test report's still the same.
The same.
It's the same data that shows how many early-stage cancers we find. It's the same sensitivity metrics and so on.
Okay. One more thing that I want to double-click on, the LDT comparison. Can you explain that a little bit, where right now you're all LDTs? It sounds like there's some discussion with the FDA around, or at least you're focused on an argument that if your label changes, you can't have other LDTs out there that are marketing themselves
as early with less robust data. Is that the point?
For me, it'd be hard to reconcile that.
Okay.
Any other LDT out there making claims with less data would be interesting if I was the FDA.
Okay. Anything you would be willing to share on expected timing with the FDA?
I mean, we are moving back and forth quickly. It all comes down to how long the negotiations are on some of these key points.
Okay.
You know, as we said, I think it is early Q1 2027.
Okay.
But we said we have updated our timeline too. Could be earlier, could be.
Okay. As I think everybody in the room and on the line probably knows, regulatory approval does not mean reimbursement, but it is required
to get reimbursement, to at least move into those discussions. Are you in active discussions with CMS?
Yeah. We've been in discussions with CMS for a while. If you remember, we started our REACH study
Yep
years ago. The REACH study has endpoints of clinical utility endpoints, similar to NHS-Galleri's, other than it's a stage 4 decrease, not a stage 3 and 4 decrease, which we demonstrated in NHS-Galleri, so we're feeling good about that. That study will supplement the CMS data that we submit.
That is a 50,000-patient study that is really intended to address some of the key questions that CMS has?
Yeah. CMS can sometimes, you can send them all the data in the world. One of the rebuttals can often be, "Well, this data isn't our population." To kind of get ahead of that, we did the study with them in conjunction with the FDA. It's under IDE, three time points, three tests, 50,000 people, and that will give them data in their population as they are looking at the NCA/NCD.
Any timelines? FDA is a little clearer. How do we think about
Yeah
the issuance of an NCD policy decision and path to reimbursement?
It will be our goal, our interest to get them to initiate an NCA right after FDA approval.
Okay.
Hopefully that is a 12-month-ish process to get through.
The NCD itself?
Yeah.
Would that be the policy decision, or is that a policy decision that concurrent with it would allow for reimbursement of Galleri?
It would be in position, so by January 1st of 2029, reimbursement could begin.
Okay. So could be at the same time, maybe not, but one way or the other, NCD done in a timely enough way to position you so that you can start to get reimbursed.
Yep
within the timeline that is outlined within the MCED bill.
Exactly.
Okay. What percentage of the addressable market gets reimbursed if this is how it plays out?
I think it's phased in 50 to 65-year-olds, then it's 50 to 66-year-olds, and it phases in every year until you get to 2035, and then it's everybody. I think the first cohort, 50 to 65, is about 8 million-10 million people, somewhere in there. And we're taking efforts to accelerate that age phase-in. It was kind of put in the legislation.
It was put in legislation as a way to manage the CBO score. But stepping back, all the advocates, all the supporters, hard to understand why you would allow a 65-year-old to have access to it and not a 66-year-old or a 67-year-old. So, we'll be really working to push that phase-in to happen faster. And we'll update you guys on that as it goes.
How important is this in driving commercial reimbursement?
It's a great question. Commercial payers have said first, "Don't talk to us until you have FDA approval." Well, positive FDA AdCom, they're now talking to us.
Yeah, that's starting to happen, right?
Yeah. We are talking to commercial payers now. I mean, as you guys all know, as you know well, Doug, that is going to be a negotiation between evidence and price. How does that weigh? We are learning more about that. We have not really gotten their thoughts until the FDA AdCom on evidence, and we will see how that plays out. High level, most of them we expect to follow Medicare. There may be some that come in before Medicare, but we will see.
How does USPSTF play into this?
Great question. Yeah. I know the way it has historically played, they have kind of- think they might have a new mandate. They might be meeting again soon. It will be interesting to see if their mandate is changed. I cannot really answer your question.
Right. Yeah, different administration.
Yeah. If it hasn't changed, then that'll drive the commercial payers to act.
All right. Earlier we talked about third quarter, what you're learning in terms of the consumer dynamic to this, the price sensitivity. Tying into that and building off of that, when you think about the expansion of the commercial organization that you pursued in the first half of this year, what are you learning about rep productivity, and based on those lessons, how do we think about commercial investment next year?
Yeah. We expect those reps that we hired, I think they were all pretty much on board early June. We did a full training in the month of June. They got educated on all the publication, not the publications, the ASCO data and so on, and hit the street. We expect them to be productive by the end of the year, and contribute fully to next year.
This is a new thing, so you don't come in with reps who've known how to do this before. We've learned that we can get them up to speed in a relatively decent amount of time. Now, scaling, when's the next time to hire more reps? With the FDA approval looming, we'll likely lean more into direct-to-consumer advertising and marketing. You haven't really seen us do that.
You've probably seen it pretty heavily from some other players in the space. We'll lean more in there, and then the right time to figure out when to expand our next sales force expansion. We're still really focused in metropolitan areas or areas where we have all the right mixture of income, age, health systems, and so on. So there's still a lot of white space out there where we don't have reps.
As part of the next decision, we'll decide, do we start to expand that white space, or do we still concentrate more where we are? Our goal is, though, to grow reps' productivity, right? To get them more efficient, more effective. Doug has heard me say this for nine, 10 years at this point, but we know that if you look at comps out there, like Exact Sciences is a great comp.
They're the largest, most successful screening company, cancer screening company. But it's a stool-based test. It's every three years. It's a different beast than an annual blood draw that fits in with your physical. So we assume we'll be more effective from a rep basis than something like Cologuard.
So you may not have to build out the full 700 to 1,000 person PC-
May not have to.
sales force.
May not have to. Don't know.
Yeah.
But you have a little time. From everybody that, from folks that we've talked to, physicians and so on, it's just an easier sale. It's a blood draw. It's not a stool kit sent to your house. What are we, cholesterol testing? No. We're not anywhere near that. No one even knows who sells cholesterol tests. We'll learn as we go. But the idea is to, we've been in the market for a while as a self-pay market, growing this. We'll have to learn with reimbursement what the right pace is to unlock those assets.
How do you think about, in general, investment next year? I want to talk about other areas where you could be investing in R&D-
in a couple minutes. But a couple of times we've talked about, hey, there's the near term, but let's keep our eyes on the fact that this is, I mean, it could be an annual test for, what, 120 million people in the U.S. alone every year. So it's a massive opportunity, but reimbursement is at least a couple years away sitting here.
So balancing those things and also recognizing, yeah, you have Exact Sciences out there, Exact Sciences Abbott out there promoting on TV. I see them during football games. You have other companies starting to run more social media campaigns. What is the importance of you guys getting more aggressive commercially in the near term, recognizing
Yeah
to some extent that's not what it's about?
Right. I mean, so I think these things are starting to merge a bit in my eyes.
Okay. Yeah.
Building awareness, building the right education base, essentially distributing tests today
Yep. Seeding the market in a way.
Probably better guarantees the future.
Yep.
We will lean more into getting patients to walk into physician's office asking for a specific test. I mean, with the consumerization of healthcare that's going on, you've got all the digital health players now. Patients are making a lot of their own healthcare decisions, and physicians are giving them what they're asking for.
So the easiest way for them to buy Galleri versus something else is for them to walk in and ask for Galleri. We've also got all the, we've got the FDA approval, physicians have all of our data and so on. We'll be leaning in more there. That'll be different. That'll be more spend from a sales and marketing side.
From a repeat testing standpoint, how are you tracking coming out of Q3 in terms of if somebody got a test done a year ago, how frequently are they coming back to do the second test?
We measure it a little bit more than a year because not everybody goes back to their physical the same day.
Yeah
Right, and gets their blood drawn. I believe it's, we're at 36% repeat test rate now within about an 18-month period.
That's been increasing.
It was 29%, I think, earlier this year, into the things that we said at J.P. Morgan. For a self-pay test, we are pretty impressed by that.
In the concierge channel, I do not know if you split it this way.
Haven't
It would be interesting to hear if that is actually higher, right? Because there is maybe less price sensitivity and more of a willingness to keep paying every year.
You will likely see more repeat testing, but you will probably also see more than one annual test.
Okay.
You'll see some people taking it quarterly or
Is that right?
Yeah.
Every-
Every couple months.
Okay. Interesting.
Yeah.
What are you learning from early physician adopters that they're going to stay on board? This kind of ties into the repeat testing. We had a panel yesterday where one of the concierge docs talked about how broadly he was using this. The repeat testing, and really pointed to part of his group of patients, his practice. He really pointed to the data, the robustness, compared to everybody else.
On one hand, it was really, really encouraging from a competitive positioning standpoint, from a penetration standpoint, and from a retention standpoint. But it's an N of one. More broadly, what are you hearing across different channels in terms of how physicians are thinking about the positioning of the test?
Yeah. Basically the same thing. We've got other physicians that have now run more than 1,000 Galleri tests in the time period, and it's all about the data. The biggest barrier is the price.
Yeah.
A physician has to decide if they want to offer this test to their patient at a certain price. They have to make a judgment whether they think the person can afford it, whether they think they're going to insult them if they offer it and they say no. So, again, back to our pricing elasticity and our pricing study, yes, it's patients taking money out of their pocket to pay, but also physicians willing to offer it.
Yeah.
As you get closer to that $500-$600 range, they're much more comfortable.
Yeah. Yeah, it's interesting, right? With the studies, but You're in a good position heading into the FDA. You've done the studies. It's been over a decade since this journey began.
Yep.
I think it would be hard to argue GRAIL doesn't have the most robust body of work going into the agency. Again, you'll be the only one approved. The reimbursement, the pricing is the challenge. From a competitive standpoint, I would think in the concierge channel and any place else where price is not an issue- or less of an issue, you're going to do well.
In other channels, where there are assays that are good assays, are allowed by the FDA where you can opt in for a test, they don't go as broad in terms of the number of cancers, but you don't have that economic challenge, right? Because it's tough to compete with free. I would think that's probably where it's a little more challenging, right, to compete. It's not the data, it's where there's economic differences. Is that fair?
Yeah. It takes longer to compete, I would say.
Yeah.
Like, once those physicians realize they are offering a test that is only every three years, that has no interventional data, and so on, they order our test.
Okay.
You know, free.
But that is where you need detailing.
Right. That's where you need detailing.
Yeah. Okay.
But yeah, free is free.
Free is free.
But it's like, we like free.
Yeah.
Free isn't always a gift, though.
Yeah.
In that case, it could end up being a massive liability for you.
Yeah.
So.
Okay. Maybe just to stick with the competition question, is there anything we're missing in terms of how we should think about competitive dynamics and how we should think about your competitive moat?
No. You've said all the reasons why we have the competitive moat. We've got regulatory-grade data. We're going to be through a regulatory process. We've got RCTs. We've got longitudinal RCTs. It's a meaningful amount of data that shows that this product is safe and effective and translates into a real-world population. It's not just case-controlled data, and I think that's really important. The differences in performance, again, you don't get to the safety profile we have at less than a 99.5% specificity.
Right.
As a physician, as even a passerby, numbers look really close, but you're at 97% or 98% specificity, you're at a five, six times higher false positive rate.
A big difference. Yeah.
A huge difference.
In this population.
Yeah, in this population.
As we think about it is hard to focus much on GRAIL beyond the opportunity, the FDA. The outlook for reimbursement. But there are other opportunities. There's adjacent products. There's the market outside the U.S. I know you're not going to tell us to focus too much on those areas, but if you'll just indulge us- for a minute, how should we think about what you could do in adjacencies- and outside the U.S.?
Yeah. Start with adjacencies to the product in the U.S. or just in general. We really refocused the company around Galleri.
Right
and de-risking it back in 2024 when we restructured the company. And we said when we de-risked Galleri, we would move on to other things. So, the entire time, we've been doing other things. And so we have an innovation platform and program that we will talk to you guys more about over the next couple months. But driving COGS down, driving sensitivity up, adding different single cancer indications to an FDA-approved platform, and so on. We also have this massive and growing quarter-over-quarter database of
Right
asymptomatic individuals. who are healthy giving us their blood, 1% of them have cancer. They probably have other diseases as well. And given advances in AI foundation models, we can likely find some of those and then expand Galleri to beyond cancer. That's another area of focus. And then other indications, there's the MRD, there's all that other stuff that we could do. But I think you guys know the playbook for all that.
Yeah. But they are not dead. They are very much alive. They are just not in focus right now.
No.
What about international?
Yeah, international, I think with the FDA approval, there are several markets that
Yeah
look at FDA approval and go, "Okay, great. Now it is time to look at doing a larger program." So we are definitely expanding our international focus.
And you already have some partnerships, right? Does FDA help those partnerships?
Yeah, I mean, FDA approval helps Samsung in Korea for sure.
Okay. Two more.
A year from now, which two or three operational metrics would best demonstrate that GRAIL on the whole is doing a good job and Aaron, the CFO, is doing a good job?
You still see me?
Yeah.
I'd say, FDA approval, any early uptake from commercial payers, whether it's small programs, pilot programs. It might not always be in the broadest population. Some of them may want to pilot it and do other things. Then progress on CMS and NCD launched, and those discussions happening. I think though not your traditional metrics, as they're more qualitative than quantitative.
Right. Yeah, but they're pretty important.
Yeah. I would be looking at those things.
Okay. What about spend? Like, and how, like, it's an interesting time, right? I mean, it looks like in Excel, you got a couple years of runway. I think you've said that. There's clearly opportunities you could lean into more. You could do more on commercial. You could do more DTC by extension. We talked about some of the adjacent opportunities. You could lean in there.
Yeah.
Especially as seemingly you're getting closer to de-risking Galleri.
Yep.
It sounds like, obviously you're aware of all of those things, but it doesn't sound like hard and fast decisions have been made on whether you lean in or you preserve runway at this point.
No, but I'd say it's pretty dynamic. I'd say, those three metrics we just talked about, the more confidence we have in those, the more likely we'd be leaning in to spend.
Okay.
On the commercial side. I'd say on the innovation side, those are lower dollar items. I think by the time we wanted to move something from development into a clinical study, then we'd probably be talking about bigger dollar items, and we'd have to have a little bit more confidence about where we're going.
The data component of this, it's not something I've heard you guys talk a lot about. It's a huge data set. Good thing is, most people you're testing, as you noted, don't have cancer. So, the time to the eventual event, whatever it is, whether it's cancer or something else, is longer. But with duration, this could be a hugely valuable data set. Do potential partners see that already?
Yeah. Yeah, partners see it. I mean, it's not your traditional pharma partner who is going to a company that has tons of cancer cases-
Right
because they're an MRD company, and then they can do so on. But there are partners who see the value in that reoccurring flywheel of healthy people coming in, giving you a biological sample, and you being able to innovate.
In a world where we're all focused on how AI is going to change healthcare and drug development and drug discovery, are there non-traditional AI companies that are interested in what we're talking about?
Okay.
I wouldn't. I mean, they all are.
Yeah.
When you've got trillions of dollars of capital, you can be interested in lots of things.
All right. Just to close, what do you think investors are not appreciating about the GRAIL story right now?
Yeah, it's a good question. I think the investors who are engaging, like our physicians, when they engage and they hear the story and they see the data, it's pretty straightforward for them, and it basically becomes a reimbursement decision. It's when do I think this thing is de-risked from a reimbursement perspective? I am hoping I figure that out before everyone else does.
Right.
Because once everyone else figures it out, it's going to be much more expensive to buy. I think we've made a ton of progress from a decade ago where we're
Absolutely
on the precipice of an FDA approval, beginning the CMS process. We've ran almost 1 million tests now, or more than 1 million tests between our studies and commercial. So we're real, we're here, and the test is working.
Okay. That's fantastic.
Yeah.
All right. Let's leave it there. Thank you very much.
Thank you, Doug.